Circulating hsa-miR-323b-3p in Huntington's Disease: A Pilot Study
Authors:
Open Access
- 5 May 2021
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 12
Abstract
The momentum of gene therapy in Huntington's disease (HD) deserves biomarkers from easily accessible fluid. We planned a study to verify whether plasma miRNome may provide useful peripheral “reporter(s)” for the management of HD patients. We performed an exploratory microarray study of whole non-coding RNA profiles in plasma from nine patients with HD and 13 matched controls [eight healthy subjects (HS) and five psychiatric patients (PP) to minimize possible iatrogenic impact on the profile of non-coding RNAs]. We found an HD-specific signature: downregulation of hsa-miR-98 (fold change, −1.5, p = 0.0338 HD vs. HS, and fold change, 1.5, p = 0.0045 HD vs. PP) and upregulation of hsa-miR-323b-3p (fold change, 1.5, p = 0.0007 HD vs. HS, and fold change, 1.5, p = 0.0111 HD vs. PP). To validate this result in an independent cohort, we quantify by digital droplet PCR (ddPCR) the presence of the two microRNA in the plasma of 33 HD patients and 49 matched controls (25 HS and 24 PP patients). We were able to confirm that hsa-miR-323b-3p was upregulated in HD and premanifest HD vs. HS and PP: the median values (first–third quartile) were 4.1 (0.9–10.53) and 5.8 (1.9–10.70) vs. 0.69 (0.3–2.75) and 1.4 (0.78–2.70), respectively, p < 0.05. No significant difference was found for hsa-miR-98. To evaluate the biological plausibility of the hsa-miR-323b-3p as a component of the disease pathophysiology, we performed a bioinformatic analysis based on its targetome and the huntingtin (HTT) interactome. We found a statistically significant overconnectivity between the targetome of hsa-miR-323b-3p and the HTT interactome (p = 1.48e−08). Furthermore, there was a significant transcription regulation of the HTT interactome by the miR-323b-3p targetome (p = 0.02). The availability of handy, reproducible, and minimally invasive biomarkers coming from peripheral miRNome may be valuable to characterize the illness progression, to indicate new therapeutic targets, and to monitor the effect of disease-modifying treatments. Our data deserve further studies with larger sample size and longitudinal design.Keywords
This publication has 33 references indexed in Scilit:
- Cognitive decline in prodromal Huntington Disease: implications for clinical trialsJournal of Neurology, Neurosurgery & Psychiatry, 2013
- Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington's disease in the TRACK-HD study: analysis of 36-month observational dataThe Lancet Neurology, 2013
- Plasma 24S-hydroxycholesterol correlation with markers of Huntington disease progressionNeurobiology of Disease, 2013
- Mutant huntingtin fragmentation in immune cells tracks Huntington’s disease progressionJournal of Clinical Investigation, 2012
- Mechanism(s) of Alteration of Micro RNA Expressions in Huntington’s Disease and Their Possible Contributions to the Observed Cellular and Molecular Dysfunctions in the DiseaseNeuroMolecular Medicine, 2012
- Hsa-miR-34b is a plasma-stable microRNA that is elevated in pre-manifest Huntington's diseaseHuman Molecular Genetics, 2011
- Widespread Shortening of 3′UTRs by Alternative Cleavage and Polyadenylation Activates Oncogenes in Cancer CellsCell, 2009
- The Bifunctional microRNA miR-9/miR-9* Regulates REST and CoREST and Is Downregulated in Huntington's DiseaseThe Journal of Neuroscience, 2008
- Plasma 24S-hydroxycholesterol and caudate MRI in pre-manifest and early Huntington's diseaseBrain, 2008
- A microRNA-based gene dysregulation pathway in Huntington's diseaseNeurobiology of Disease, 2008